Progenics Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
84.45 M |
Public Float |
52.34 M |
Progenics Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.9 |
Market Cap |
$496.59 M |
Shares Outstanding |
84.74 M |
Public Float |
83.85 M |
Address |
One World Trade Center New York New York 1000 United States |
Employees | - |
Website | http://www.progenics.com |
Updated | 07/08/2019 |
Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. |